What are the key changes in executive compensation reported in this filing?

This filing details the 2009 base salaries and 2008 bonus awards for Gilead's executive officers. It also outlines increases in target bonus percentages for certain senior roles and the granting of new stock options and performance shares for 2009. Notably, the CEO's target bonus percentage was increased.

How are the performance shares structured, and what are the key metrics for their payout?

Performance shares awarded in 2009 are tied to Gilead's performance over a three-year period (2009-2011). The number of actual shares convertible ranges from 0% to 200% of the grant based on the company's total shareholder return (TSR) and revenue growth relative to the AMEX Biotech-Pharmaceutical Index. Higher percentile rankings in both metrics lead to higher conversion rates, with a maximum of 200% for performance at or above the 80th percentile in both categories.

Under what circumstances can performance shares vest early?

Performance shares can vest partially or fully in advance under specific conditions: death or disability of the executive, retirement after completing at least one year of service within the performance period, or a change in control of the company. In a change in control, performance shares may convert into vested shares equal to 100% of the grant or a potentially higher amount based on an abbreviated performance period.

What is the significance of the stock option exercise price?

The stock options were granted with an exercise price of $47.20 per share, which was the closing price of Gilead's common stock on January 20, 2009. This means that for these options to be profitable for the executive, the stock price must rise above $47.20 per share by the time the options are exercised, aligning executive interests with stock appreciation.

GILD 8-K: Leadership Changes

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K report on January 27, 2009, detailing executive compensation and equity awards for the 2008 and 2009 fiscal years. The Compensation Committee of the Board of Directors established 2009 base salaries and determined 2008 bonus awards for its named executive officers, including the CEO, John C. Martin. The report also outlines the granting of stock options and performance shares for 2009, with award values tied to future company performance relative to a peer group index. These compensation adjustments and new equity grants signal the company's commitment to retaining and motivating its key leadership as it navigates its strategic objectives. The performance-based nature of the equity awards, specifically the performance shares, introduces a significant component of shareholder alignment, as executive payouts are directly linked to the company's total shareholder return (TSR) and revenue growth compared to industry peers over a three-year period. Investors should monitor these performance metrics as an indicator of management's focus and potential future value creation.

Key Highlights

1Gilead's Compensation Committee set 2009 base salaries and approved 2008 bonus awards for its executive officers.
2CEO John C. Martin received a 2008 bonus of $1,651,650 and a 2009 base salary of $1,250,000.
3Significant increases in base salaries for several executives, including the CFO Robin L. Washington, whose salary rose from an unstated 2008 amount to $530,000 for 2009.
4The target bonus award for the CEO for 2009 was increased from 110% to 125% of base salary.
5Stock options were granted to executive officers with an exercise price of $47.20 per share, vesting over five years.
6Performance shares were awarded, with the number of actual shares convertible ranging from 0% to 200% of the grant, based on relative TSR and revenue growth compared to the AMEX Biotech-Pharmaceutical Index over a three-year period (2009-2011).
7Performance share payouts can be accelerated upon death, disability, retirement (after one year of service in the performance period), or a change in control event.

GILEAD SCIENCES, INC. 8-K Report, Executive Changes (Jan 27, 2009)

Summary

Key Highlights

Frequently Asked Questions